News Release

Twist Bioscience Launches High Throughput Antibody Production Platform

Apr 28, 2022

-- Gene to Antibody Production Workflow Enables Customers to Turn Digital DNA Sequences into Purified IgG Antibodies --

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 28, 2022-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of synthetic DNA using its silicon platform, today announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.

In the antibody development pipeline, researchers often experience a bottleneck when transitioning from display library panning to antibody characterization. Antibody discovery platforms like phage-display and single B-cell sequencing make it possible to identify hundreds to thousands of potentially high-affinity antibodies for characterization and development. However, further study of these hits requires expression as full-length antibodies, a process that is often low-throughput, resource-intensive, costly, and a significant hurdle for advancement.

“The low-throughput, resource-intensive process of antibody variant characterization can be a costly bottleneck in the discovery pipeline. So, this unique offering, which provides the ability, in one place, to easily order gene sequences and receive the resulting antibodies, can make the timeline for antibody discovery and optimization programs more efficient. I’ve always said that Twist enables our customers to forgo the need to do cloning themselves, i.e. friends don’t let friends clone. Similarly, this new offering could have the same impact on high throughput antibody screening, i.e. friends don’t let friends make their own screening antibodies,” said Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

The new offering will be highlighted at PEGS Boston (www.pegsummit.com), taking place May 2-6, 2022. For more information on how the high throughput antibody offering is empowering drug discovery, please attend our oral presentation entitled “Writing the Future of Biologics” by our CSO, Aaron Sato, on Monday, May 2nd at 2:50 PM EST. We will also have numerous posters throughout the event that use the product as well.

Twist High Throughput Antibody Production Workflow
The Twist High Throughput Antibody Production provides a comprehensive and efficient solution to antibody production and purification. The process begins with antibody sequences being entered into Twist’s eCommerce ordering platform, where bioinformatic screening and gene scoring is used to filter out potentially non-viable sequences. From there, synthetic DNA is generated, which is either cloned into one of Twist’s IgG scaffold vectors, or a vector of the customer’s choice. Twist’s silicon-based DNA synthesis platform enables the simultaneous production of up to thousands of antibody genes, which enables flexible production of tens to thousands of distinct antibodies. The antibodies are sequenced to ensure that the precise order has been cloned, every time. These antibodies are then produced in HEK293 cells, resin purified, and are usually delivered within 35 business days of ordering.

About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation the expected ability of Twist High Throughput Antibody Production to increase the efficiency of antibody discovery and optimization programs, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-Q filed with the Securities and Exchange Commission on February 9, 2022, and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Angela Bitting
Twist Bioscience
(925) 202-6211
abitting@twistbioscience.com

Source: Twist Bioscience Corporation